Agios Pharma (AGIO)
NASDAQ:AGIO
Want to see AGIO full AI Analyst Report?
AGIO Stock Chart & Stats
$35.14
-$0.03(-0.09%)
At close: 4:00 PM EST
$35.14
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)902.68K
Market Cap
$1.60B
Enterprise Value$1.53B
Total Cash (Recent Filing)$737.04M
Total Debt (Recent Filing)$35.74M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Jul 30, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.25
Shares Outstanding59,471,607
10 Day Avg. Volume884,537
30 Day Avg. Volume902,680
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue23.11
Enterprise Value/Gross Profit28.16
Enterprise Value/Ebitda-3.25
Forecast
1Y Price Target
$38.29Price Target Upside8.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.59
Revenue Forecast (FY)$91.59M
Bulls Say, Bears Say
Bulls Say
Early Commercial UptakeInitial Aqvesme prescriptions and REMS certifications across academic and community physicians indicate early market acceptance that could underpin a steady launch trajectory.
Established Safety ProfileMitapivat's safety record from two approved uses could streamline regulatory review and bolster physician confidence, supporting uptake in a new indication.
Market OpportunitySickle cell disease represents a substantial unmet medical need with few approved therapies, giving mitapivat a large addressable market that could drive meaningful sales if the indication is approved.
Bears Say
Clinical Efficacy QuestionsThe Phase 3 trial met the hemoglobin endpoint but missed significance on the pain crisis measure, raising doubts about relying on that trial alone for full approval and potentially necessitating further studies.
Commercialization HeadwindsREMS certification and prior authorization processes can delay prescription fulfillment and introduce a multi-week lag before revenue recognition, slowing near-term sales realization.
Regulatory Trial UncertaintyUndisclosed specifics for the confirmatory trial design leave uncertainty about FDA expectations and create a key gating risk for regulatory approval.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.60B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Jul 30, 2026 which is in 83 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Apr 29, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.803 by $0.113.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.61.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,471,607 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.803. Following the earnings report the stock price went up 13.105%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.29 (8.95% Upside)
$38.29 (8.95% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.04%
12-Months-Change
Fundamentals
Return on Equity
-34.11%
Trailing 12-Months
Asset Growth
-23.82%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial momentum and significant regulatory and pipeline progress—highlighted by 138% YoY revenue growth, a successful AQVESME U.S. launch with 242 prescriptions, planned sNDA submission for mitapivat in sickle cell disease, and a robust cash position (> $1B). Offsetting items included rising R&D and SG&A spend, limited ex‑U.S. revenue and quarter‑to‑quarter variability, a prescription‑to‑initiation lag as launch broadens, a 60% lower tebapivat exposure signal in low‑risk MDS necessitating higher‑dose evaluation, and some regulatory/competitive uncertainty that will need to be resolved by upcoming data and confirmatory trials. Overall, the positives (strong growth, launch execution, regulatory progress and ample liquidity) materially outweigh the near‑term challenges and risks.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$38.29
▲(8.95% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
1.11% Insiders
25.79% Mutual Funds
4.95% Other Institutional Investors
48.36% Public Companies and
Individual Investors